Search results for "Forming"

showing 10 items of 1719 documents

Regulation of PTHrP and PTH/PTHrP receptor by extracellular Ca2+ concentration and hormones in the breast cancer cell line 8701-BC.

2000

AbstractIt was previously reported that 8701-BC breast tumour cells express the gene for parathyroid hormonerelated peptide (PTHrP) and PTH/PTHrP receptor (PTHrPR) and release immunoreactive PTHrP (iPTHrP) into the extracellular medium. Since the regulation of PTHrP and PTHrPR by breast cancer cells has been poorly investigated so far, we have chosen the 8701- BC cell line as a model system to investigate whether alterations in the extracellular Ca[2+] concentration ([Ca[2+]]) and treatment with some wellknown differentiation agents for breast cells, such as dimethyl sulfoxide, hydrocortisone, progesterone, prolactin, alltrans retinoic acid and transforming growth factorβ1 might (i) modulat…

medicine.medical_specialtyTranscription GeneticRNA SplicingClinical BiochemistryRetinoic acidCodon InitiatorBreast NeoplasmsTretinoinBiochemistrychemistry.chemical_compoundTranscription (biology)Transforming Growth Factor betaInternal medicinemedicineExtracellularTumor Cells CulturedHumansProtein IsoformsRNA MessengerPromoter Regions GeneticMolecular BiologyGeneChemistryParathyroid Hormone-Related ProteinProteinsProlactinHormonesNeoplasm ProteinsEndocrinologyGene Expression RegulationCell cultureRNA splicingReceptors Parathyroid HormoneCalciumExtracellular Spacehormones hormone substitutes and hormone antagonistsHormoneBiological chemistry
researchProduct

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice

2012

Background & Aims CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo . Methods Mice with liver-specific deletion of CYLDexon7/8 ( CYLD FF xAlbCre ) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated …

medicine.medical_specialtyTumor suppressor geneBiliary Tract DiseasesIn Vitro TechniquesBiologymedicine.disease_causeDimethylnitrosamineDeubiquitinating Enzyme CYLDMiceRisk FactorsFibrosisInternal medicinemedicineAnimalsHomeostasisGenetic Predisposition to DiseaseHepatologyLiver NeoplasmsExonsTransforming growth factor betamedicine.diseaseFibrosisMice Mutant StrainsDeubiquitinating Enzyme CYLDMice Inbred C57BLGene expression profilingCysteine EndopeptidasesDisease Models AnimalPhenotypeEndocrinologyLiverPhenobarbitalHepatocellular carcinomaCancer researchbiology.proteinCell activationCarcinogenesisGene DeletionJournal of Hepatology
researchProduct

Estradiol Stimulates Vasodilatory and Metabolic Pathways in Cultured Human Endothelial Cells

2009

Vascular effects of estradiol are being investigated because there are controversies among clinical and experimental studies. DNA microarrays were used to investigate global gene expression patterns in cultured human umbilical vein endothelial cells (HUVEC) exposed to 1 nmol/L estradiol for 24 hours. When compared to control, 187 genes were identified as differentially expressed with 1.9-fold change threshold. Supervised principal component analysis and hierarchical cluster analysis revealed the differences between control and estradiol-treated samples. Physiological concentrations of estradiol are sufficient to elicit significant changes in HUVEC gene expression. Notch signaling, actin cyt…

medicine.medical_specialtyUmbilical Veinsmedicine.drug_classScienceEstrogen receptorBiologyAmidohydrolasesTransforming Growth Factor beta1chemistry.chemical_compoundInternal medicinemedicineCluster AnalysisEstrogen Receptor betaHumansEstrogen receptor betaCell Biology/Gene ExpressionCells CulturedOligonucleotide Array Sequence AnalysisRegulation of gene expressionPrincipal Component AnalysisMultidisciplinaryEstradiolPhysiology/EndocrinologyReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingQPhysiology/Cardiovascular Physiology and CirculationREstrogen Receptor alphaEndothelial CellsReproducibility of ResultsActin cytoskeletonVasodilationEndocrinologychemistryGene Expression RegulationEstrogenCyclooxygenase 1MedicineSignal transductionAsymmetric dimethylarginineEstrogen receptor alphahormones hormone substitutes and hormone antagonistsMetabolic Networks and PathwaysResearch ArticleSignal TransductionPLoS ONE
researchProduct

Involvement of Different networks in mammary gland involution after the pregnancy/lactation cycle: Implications in breast cancer

2015

Early pregnancy is associated with a reduction in a woman's lifetime risk for breast cancer. However, different studies have demonstrated an increase in breast cancer risk in the years immediately following pregnancy. Early and long-term risk is even higher if the mother age is above 35 years at the time of first parity. The proinflammatory microenvironment within the mammary gland after pregnancy renders an "ideal niche" for oncogenic events. Signaling pathways involved in programmed cell death and tissue remodeling during involution are also activated in breast cancer. Herein, the major signaling pathways involved in mammary gland involution, signal transducer and activator of transcripti…

medicine.medical_specialtybiologyClinical BiochemistryMammary glandCell BiologyTransforming growth factor betamedicine.disease_causemedicine.diseaseBiochemistryChromatin remodelingmedicine.anatomical_structureEndocrinologyBreast cancerInternal medicineGeneticsmedicinebiology.proteinCancer researchInvolution (medicine)Signal transductionCarcinogenesisMolecular BiologyMammary gland involutionIUBMB Life
researchProduct

Clinical and genetic update of corneal dystrophies.

2019

The International Committee for Classification of Corneal Dystrophies (IC3D) distinguishes between 22 distinct forms of corneal dystrophy which are predominantly autosomal dominant, although autosomal recessive and X-chromosomal dominant patterns do exist. Before any genetic examination, there should be documentation of a detailed corneal exam of as many affected and unaffected family members as possible, because detailed phenotypic description is essential for accurate diagnosis. Corneal documentation should be performed in direct and indirect illumination at the slit lamp with the pharmacologically dilated pupil. For the majority of the corneal dystrophies, a phenotype-genotype correlatio…

medicine.medical_specialtygenetic structuresGenetic ExaminationCorneal dystrophyCollagen Type ITransforming Growth Factor beta1Cellular and Molecular NeuroscienceCorneaOphthalmologyGenotypemedicineHumansGenetic Predisposition to DiseaseCorneal Dystrophies Hereditarybusiness.industryEpithelium Cornealmedicine.diseasePhenotypeeye diseasesSensory SystemsCollagen Type I alpha 1 ChainOphthalmologyEpithelial recurrent erosion dystrophymedicine.anatomical_structuresense organsDifferential diagnosisbusinessTGFBIExperimental eye research
researchProduct

The Relationship between the Transforming Growth Factor β1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects

2009

The distribution of the T29C TGFβ1 gene polymorphism was analyzed in 198 hypertensives with left ventricular hypertrophy (LVH) and in 235 hypertensives without LVH. Circulating TGFβ1 levels, procollagen type III levels, microalbuminuria, and left ventricular geometry and function were evaluated in all the hypertensives with LVH subgrouped according to T29C TGFβ1 gene polymorphism. Circulating TGFβ1 was evaluated by ELISA technique, procollagen type III by a specific radioimmunoassay, microalbuminuria by radioimmunoassay, and left ventricular geometry and function by echocardiography. All groups were comparable for gender, age, and sex. Regarding T29C TGFβ1 gene polymorphism, prevalence of T…

medicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaArticle SubjectLeft ventricular hypertrophyExcretionGene PolymorphismInternal medicineGenotypeInternal MedicinemedicineTransforming Growth Factor β1 T29C; Gene Polymorphism; Left Ventricular Geometry; Hypertensioncardiovascular diseasesTransforming Growth Factor β1 T29CEjection fractionbusiness.industryLeft Ventricular GeometryRadioimmunoassaymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheSettore MED/11 - Malattie Dell'Apparato CardiovascolareEndocrinologylcsh:RC666-701HypertensionMicroalbuminuriaGene polymorphismbusinessResearch ArticleTransforming growth factorInternational Journal of Hypertension
researchProduct

Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anti…

2012

Abstract Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist such as warfarin. However, this option is not without its limitations, as the anticoagulant effect of warfarin is associated with high inter- and intra-patient variability and patients must be regularly monitored to ensure that anticoagulation is within the narrow target therapeutic range. Several novel oral anticoagulant agents are in the advanced stages of development for VTE treatment, some of which are given after an initial period of heparin treatment, in line with current p…

medicine.medical_specialtymedicine.drug_classDeep veinReviewTherapeutic indexRecurrencemedicinecardiovascular diseasesIntensive care medicinebusiness.industryHeparinlcsh:RC633-647.5AnticoagulantBleedingWarfarinAnticoagulantsHeparinlcsh:Diseases of the blood and blood-forming organsHematologyVitamin K antagonistmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureVitamin K antagonistsbusinessmedicine.drugVenous thromboembolismThrombosis Journal
researchProduct

Impact of single-dose application of TGF-β, copper peptide, stanozolol and ascorbic acid in hydrogel on midline laparatomy wound healing in a diabeti…

2012

Despite numerous advances and improvements in surgical techniques the incidence of incisional hernias after laparotomy remains high. The aim of this study was to investigate possible effects of single application of ascorbic acid, stanozolol, a synthetic anabolic steroid, copper peptide and transforming growth factor-β (TGF-β) on laparotomy wound healing in an incisional wound model in diabetic mice. After diabetes induction with streptozotozin in Balb-c mice, midline laparatomies were carried out. Closure of the linea alba was followed by single-dose application of the agents dissolved in a hydrogel before skin closure. The functional outcome was assessed in terms of maximum tensile streng…

medicine.medical_specialtymedicine.medical_treatmentFibrillar CollagensAscorbic AcidBiologyDiabetes Mellitus ExperimentalCollagen Type IIICicatrixMiceTransforming Growth Factor betaInternal medicineDiabetes mellitusLaparotomyTensile StrengthGeneticsmedicineAnimalsStanozololLaparotomyMice Inbred BALB CWound HealingHydrogelsGeneral MedicineAscorbic acidmedicine.diseaseDisease Models Animalmedicine.anatomical_structureEndocrinologyLinea alba (abdomen)FemaleWound healingPeptidesAnabolic steroidCopperStanozololmedicine.drugInternational journal of molecular medicine
researchProduct

The EHA research roadmap

2021

International audience; In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research(1) aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1-2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published…

medicine.medical_specialtymedicine.medical_treatmentPlatelet disorderClinical scienceHematopoietic stem cell transplantation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicinemedicineDiseases of the blood and blood-forming organsIntensive care medicine030304 developmental biology0303 health sciencesHematologybusiness.industryTransfusion medicineHematologyHemostatic Disorders3. Good healthBlood DisorderEuropean policy[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologiePerspective[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieRC633-647.5businessHemaSphere
researchProduct

Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules

2009

Splenectomy and splenic irradiation (SI) are the sole treatment modalities to control drug resistant splenomegaly in patients with myelofibrosis (MF). SI has been used in poor surgical candidates but optimal total dose and fractionation are unclear. We retrospectively reviewed 14 MF patients with symptomatic splenomegaly. Patients received a median of 10 fractions in two weeks. Fraction size ranged from 0.2–1.4 Gy, and total dose varied from 2–10.8 Gy per RT course. Overall results indicate that 81.8% of radiation courses achieved a significant spleen reduction. Splenic pain relief and gastrointestinal symptoms reduction were obtained in 94% and 91% of courses, respectively. Severe cytopeni…

medicine.medical_specialtypalliationmedicine.medical_treatmentSplenectomyMyelofibrosisSpleenSubgroup analysisGastroenterologyArticleInternal medicineMedicinemyelofibrosis; splenomegaly; palliation; radiotherapy; low-dose irradiationMyelofibrosisAdverse effectradiotherapylow dose irradiationsplenomegalylcsh:RC633-647.5business.industrylow-dose irradiation.lcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTolerabilityToxicitybusinessHematology Reports
researchProduct